newsfilter
← Latest News
GlobeNewswire·

Pardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2 Infections

Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral activity, safety, and efficacy of PBI-0451 versus placebo Interim data from Phase 2 anticipated in Q1 2023 CARLSBAD, Calif., Sept. 13, 2022 (GLOBE NEWSW